GC
NWBO

Guggenheim Capital’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History

Guggenheim Capital’s Portfolio NWBO Stock Details NWBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-27,644
Closed -$15K – 3099
2016
Q3 		$15K Buy
27,644
+15,393
+126% +$7.04K ﹤0.01% 2850
2016
Q2 		$7K Sell
12,251
-1,039
-8% -$1.11K ﹤0.01% 2862
2016
Q1 		$20K Sell
13,290
-5,470
-29% -$10.8K ﹤0.01% 2827
2015
Q4 		$60K Buy
18,760
+7,154
+62% +$34.4K ﹤0.01% 2884
2015
Q3 		$73K Buy
11,606
+760
+7% +$7.1K ﹤0.01% 2826
2015
Q2 		$108K Sell
10,846
-1,122
-9% -$9.83K ﹤0.01% 2891
2015
Q1 		$88K Buy
11,968
+1,117
+10% +$7.52K ﹤0.01% 2874
2014
Q4 		$58K Buy
+10,851
New +$55.5K ﹤0.01% 2906
2014
Q3 		– Sell
-18,877
Closed -$126K – 3314
2014
Q2 		$126K Buy
18,877
+4,951
+36% +$31.5K ﹤0.01% 2975
2014
Q1 		$101K Buy
13,926
+3,166
+29% +$18.8K ﹤0.01% 3030
2013
Q4 		$41K Buy
10,760
+638
+6% +$2.47K ﹤0.01% 3079
2013
Q3 		$34K Buy
+10,122
New +$35.2K ﹤0.01% 2980

Other funds holding NWBO

WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return
CDH
Charles D. Hyman $1.79B AUM 17.18% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
MBT
Montecito Bank & Trust Santa Barbara, California $668M AUM 24.84% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BW
Biegel & Waller Columbia, Maryland $179M AUM 1.6% 1-Year Est. Return
MPI
Mairs & Power Inc St Paul, Minnesota $9.79B AUM 20.6% 1-Year Est. Return

Guggenheim Capital's NWBO Position: Q4 2016 in Review

Guggenheim Capital sold out of Northwest Biotherapeutics, Inc. Common stock (NWBO) in Q4 2016, closing a stake of 27,644 shares — an estimated $15K sold.

Guggenheim Capital first reported a position in NWBO in Q3 2013 and held it in 12 quarters. The position peaked at $126K in Q2 2014. 8 funds tracked by Wall St. Rank hold NWBO as of Q4 2016.

  • Guggenheim Capital reported no remaining Northwest Biotherapeutics, Inc. Common stock position as of Q4 2016 after selling out during the quarter.
  • Guggenheim Capital sold 27,644 Northwest Biotherapeutics, Inc. Common stock shares in Q4 2016, an estimated $15K.
  • Guggenheim Capital first reported a position in Northwest Biotherapeutics, Inc. Common stock in Q3 2013 and held it in 12 quarters.
  • Guggenheim Capital's Northwest Biotherapeutics, Inc. Common stock position peaked at $126K in Q2 2014.
  • 8 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. Common stock as of Q4 2016.

Based on Guggenheim Capital's 13F filing for Q4 2016, filed 14 Feb 2017.